Provided by Tiger Trade Technology Pte. Ltd.

Incyte

121.35
-1.8500-1.50%
Post-market: 121.00-0.3500-0.29%17:27 EDT
Volume:1.62M
Turnover:197.58M
Market Cap:24.60B
PE:15.46
High:124.23
Open:123.00
Low:121.03
Close:123.20
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.11
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.88
PE(LYR):18.93

Loading ...

Halozyme Appoints Jim Daly to Board of Directors

Reuters
·
2 hours ago

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Yesterday

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

Incyte management to meet with Oppenheimer

TIPRANKS
·
Sep 29

MiniMed Names Sheila Denton General Counsel, Corporate Secretary

Reuters
·
Sep 28

Mirum Rises on FDA Nod for Rare Bone Disorder Drug

Reuters
·
Sep 28

Incyte Price Target Raised to $152.00/Share from $150.00 by HC Wainwright & Co.

Dow Jones
·
Sep 28

Incyte Corporation : H.c. Wainwright Raises Target Price to $152 from $150

THOMSON REUTERS
·
Sep 28

JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating

MT Newswires Live
·
Sep 28

Incyte, Mirum's Treatment of Rare Genetic Ossification Condition Approved by US FDA

MT Newswires Live
·
Sep 28

Incyte : JP Morgan Raises Target Price to $123 from $120

THOMSON REUTERS
·
Sep 28

Incyte (INCY) Gets a Hold from Bernstein

TIPRANKS
·
Sep 26

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (Zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Sep 26

FDA approves Incyte’s Atebrioz for fibrodysplasia ossificans progressiva

TIPRANKS
·
Sep 26

US FDA Approves Mirum's Drug for Rare Bone Disorder

Reuters
·
Sep 26

FDA: Approves Atebrioz (Zilurgisertib) for Fibrodysplasia Ossificans Progressiva in Adults & Pediatric Patients 12 Years + - Website

THOMSON REUTERS
·
Sep 26

FDA : Atebrioz Recommended Dosage 100 Mg Once Daily

THOMSON REUTERS
·
Sep 26

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 23

Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says

MT Newswires Live
·
Sep 22

Incyte Price Target Maintained with a $109.00/Share by RBC Capital

Dow Jones
·
Sep 22